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Enterovirus 71 (EV71) was implicated in a widespread outbreak of hand-foot-and-mouth
disease (HFMD) across the Asia Pacific area since 1997 and has also been reported
sporadically in patients with brain stem encephalitis. Neurogenic shock with pulmonary
edema (PE) is a fatal complication of EV71 infection. Among inotropic agents, milrinone
is selected as a therapeutic agent for EV71- induced PE due to its immunopathogenesis.
Milrinone is a type III phosphodiesterase inhibitor that has both inotropic and vasodilator
effects. Its clinical efficacy has been shown by modulating inflammation, reducing
sympathetic over-activity, and improving survival in patients with EV71-associated PE.
Milrinone exhibits immunoregulatory and anti-inflammatory effects in the management
of systemic inflammatory responses in severe EV71 infection.
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EPIDEMIOLOGY AND CLINICAL SPECTRUM
Enteroviruses can result in a wide range of clinical illnesses, including herpangina, hand-foot-
and-mouth disease (HFMD), and occasionally causes neurological complications, meningitis,
encephalitis and poliomyelitis-like paralysis. Enterovirus 71 (EV71), which was first identified in
1969, causes meningitis (Schmidt et al., 1974). In Taiwan the initial outbreak of EV71 infection
of 1998, total number of cases estimated at around 1.5 million, among which 405 had severe
diseases and 78 died (Ho et al., 1999). Approximately 30% of hospitalized HFMD patients
with EV71 infection developed more complicated disease (Chang et al., 1999) including aseptic
meningitis, acute flaccid paralysis, brain stem encephalitis (BE), autonomic nervous system (ANS)
dysregulation, and pulmonary edema (PE), which in some cases can be fatal (Wang et al., 1999,
2003; Wang and Liu, 2009, 2014).
MANAGEMENT
Epinephrine
For the classical vasopressor–inotropes, such as epinephrine, the mechanisms of increasing
myocardial contractility are primarily based on stimulating α- or β-adrenergic receptors located on
the cell membrane of myocardial cells. Epinephrine exerts its cardiovascular effects by stimulating
the α- or β-adrenergic receptors in a dose-dependent manner. At high doses, epinephrine also
stimulates the vascular and cardiac α1-receptors causing vasoconstriction and increased inotropy.
The net hemodynamic effects of epinephrine administration are significant increases in blood
pressure and systemic blood flow. EV71-infected patients in the phase of ANS dysregulation
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display hypertension, tachycardia, and severe peripheral
vasoconstriction. Once the surge of sympathetic over-activity
resulted in PE, the cardiopulmonary failure followed. The
plasma levels of epinephrine in EV71-infected patients
with ANS dysregulation and PE were markedly high
(Liao et al., 2015). Furthermore, the percentages EV71-
infected cells were increased in THP-1 and Jurkat cells via
treatment with epinephrine. At least twofold increase in
virus titer was observed in EV71-infected A549, SK-N-SH,
and hPBMCs after treatment with epinephrine (Liao et al.,
2015). Furthermore, catecholamines have many disadvantages,
including increased myocardial oxygen consumption, heart
rate, afterload, and the risk of dysrhythmias (Wessel,
2001). Therefore, epinephrine is contraindicated in these
patients.
Milrinone
Patients with EV71 associated PE have a high case-fatality
rate around 80–90%. Without prompt management, the
fatality may occur within 6–12 h after onset of BE. Milrinone,
a bipyridine derivative and phosphodiesterase (PDE) III
inhibitor, has both inotropic and vasodilatation characters.
Milrinone enhances myocardial contractility, promotes
myocardial relaxation, and decreases vascular tone in the
systemic and pulmonary vascular beds without excessive
increases in myocardial oxygen consumption (Shipley
et al., 1996). It exerts its cardiovascular effects through
the inhibition of cyclic adenosine 3′,5′-monophosphate
(cAMP) degradation but have no interaction with the
adrenergic receptors nor do they inhibit Na-K ATPase.
Inhibition of cAMP degradation by intracellular PDE3 may
attenuate inflammation, reduce edema formation, improve
endothelial function, and induce pulmonary vasodilation
(Hayashida et al., 1999). A pilot study was designed to
evaluate the potential therapeutic effects of milrinone in
the treatment of patients with EV71-induced PE (Wang
et al., 2005). The mortality rate, sympathetic activity and
inflammatory cells were significantly lower in patients
with milrinone treatment than patients without milrinone
treatment.
Clinical Outcome
Meyer et al. (2011) reviewed the randomized and quasi-
controlled trials of milrinone treatment in children with
low cardiac output syndrome after congenital heart surgery
(Hoffman et al., 2003; Cai et al., 2008) and in non-
hyperdynamic septic shock (Barton et al., 1996; Lindsay
et al., 1998). They concluded these trials have shown
significantly improved cardiovascular function, however,
none of the studies demonstrated improved long-term survival
and reduced long-term morbidity (Meyer et al., 2011). In
a randomized, controlled study, the 1-week mortality of
patients with EV71-associated PE was significantly lower
in patients with milrinone treatment than patients without
milrinone treatment. The median duration of ventilator-
free days was also longer in the milrinone treatment
group (Chi et al., 2013). The effectiveness and efficacy
of milrinone treatment in patients with EV71 associated
PE has been proven in historically controlled (Wang
et al., 2005) and randomized controlled studies (Chi et al.,
2013).
Immunoregulation
Phosphodiesterase inhibitors can regulate the activity of immune
cells by increasing intracellular levels of cyclic nucleotides.
Milrinone was administered to mice either once or five times
at 24 h intervals and resulted in decreased percentages of B
cells (CD19+) and increased percentages of T cells (CD3+,
CD4+, CD8+) in splenocyte subpopulations (Szczypka and
Obmiñska-Mrukowicz, 2010). The expression frequency of
regulatory T cell (Tregs) profiles CD4−CD8−, CD4+Foxp3+,
and CD4+CD25+Foxp3+ decreased significantly in the
advanced stages of EV71 infection, in patients with ANS
dysregulation or PE. Fu et al. (2009) suggested the decreased
CD4+CD25+Foxp3+expression frequency in severe EV71
infection may associate with the decreased plasma level of TGF-β
and increased plasma level of IL-6. Plasma concentrations of
cAMP were significantly decreased in patients with EV71-
induced ANS dysregulation or PE compared with patients
with EV71-induced HFMD or BE. The modulating effect of
PDE inhibitors on lymphocyte subpopulations is related to
their influence on synthesis and release of cytokines (Szczypka
and Obmiñska-Mrukowicz, 2010). Intravenous administration
of milrinone reduced the levels of serum pro-inflammatory
cytokines in patients in a prospective randomized clinical study
(Hayashida et al., 1999). cAMP has been considered to have
general anti-inflammatory activity, can inhibit inflammation-
related chemotaxis, lysosomal enzyme and histamine release,
mitogenesis, and lymphocyte-mediated cytotoxicity (Moore and
Willoughby, 1995). Milrinone has direct effect on decreasing
the production of pro-inflammatory cytokines by elevating
cAMP and inhibiting the NF-κB pathway (Barin and Cˇiháková,
2013). Milrinone therapy not only increased the expression
frequency of CD4+Foxp3+ and plasma levels of cAMP in
severe EV71 infection but also reduced the plasma levels of
cytokines, IL-6, IL-8, IL-10, and IL-13 (Wang et al., 2005,
2014).
Challenges
Milrinone provides a useful therapeutic approach for treating
life threatening EV71 infections. A low-dose β-blocker in
combination with milrinone improved cardiac function in
acute decompensated heart failure patients with tachycardia
(Kobayashi et al., 2012). Liao et al. (2015) also showed
β-blocker reduced the percentages of EV71-infected cells in
THP-1, Jurkat cells and hPBMCs with norepinephrine and
epinephrine treatment. The combination of β-blockade with
PDE III inhibition is counterintuitive; they have opposing
effects on intracellular cAMP concentrations. A pharmacological
clamp is effectively applied to the heart, holding it at a given
contractility and rate, opposing fluctuations in endogenous
catecholamines (McNeilly, 2014). Acute β-blockade in the
presence of a PDE III inhibitor has been shown to be feasible and
suggested as cardioprotective in sepsis (Schmittinger et al., 2008;
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Morelli et al., 2013). Therefore, standard therapy with milrinone
in patients EV71-induced PE, β-blocker may be considered as an
adjunct therapy.
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